Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Resistance to MET/VEGFR2 Inhibition by Cabozantinib Is Mediated by YAP/TBX5-Dependent Induction of FGFR1 in Castration-Resistant Prostate Cancer
Filippos Koinis et al.
CANCERS (2020)
Establishment and Characterization of a Topotecan Resistant Non-small Cell Lung Cancer NCI-H460/TPT10 Cell Line
Zi-Ning Lei et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Enzyme and Transporter Kinetics for CPT-11 (Irinotecan) and SN-38: An Insight on Tumor Tissue Compartment Pharmacokinetics Using PBPK
Yingfang Fan et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2019)
HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity
Basmina Parmakhtiar et al.
MOLECULAR CANCER RESEARCH (2019)
The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf et al.
DRUG RESISTANCE UPDATES (2019)
The ABCG2 multidrug transporter is a pump gated by a valve and an extracellular lid
Narakorn Khunweeraphong et al.
NATURE COMMUNICATIONS (2019)
Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
Lais Osmani et al.
SEMINARS IN CANCER BIOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Dose translation between laboratory animals and human in preclinical and clinical phases of drug development
Anroop Nair et al.
DRUG DEVELOPMENT RESEARCH (2018)
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib
Guan-Nan Zhang et al.
PHARMACOLOGICAL RESEARCH (2017)
Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
Jun Li et al.
ONCOTARGET (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
L. Zhou et al.
ONCOGENE (2016)
ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
Maryam Hosseini Hasanabady et al.
JOURNAL OF BIOSCIENCES (2016)
Multidrug Resistance Proteins (MRPs) and Cancer Therapy
Yun-Kai Zhang et al.
AAPS JOURNAL (2015)
Engineering cancer microenvironments for in vitro 3-D tumor models
Waseem Asghar et al.
MATERIALS TODAY (2015)
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport-an Update
Qingcheng Mao et al.
AAPS JOURNAL (2015)
Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo
Kamlesh Sodani et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models
Amit K. Tiwari et al.
CANCER LETTERS (2013)
Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non-Small-Cell Lung Cancer
Steven F. Powell et al.
CLINICAL LUNG CANCER (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells
Giovanna D'Onofrio et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Jean-Pierre Gillet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
ABC multidrug transporters: structure, function and role in chemoresistance
Frances J. Sharom
PHARMACOGENOMICS (2008)
Chemotherapy resistance and oncogene expression in non-small cell lung cancer
Thomas A. d'Amato et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2007)
Multidrug resistance and cancer: The role of the human ABC transporter ABCG2
KFK Ejendal et al.
CURRENT PROTEIN & PEPTIDE SCIENCE (2002)
Share Paper
